Castle Biosciences Q2 revenue $22.8M (+79% YoY); raises FY2021 guidance to $89-93M

CASTLE BIOSCIENCES INC

2021-Q2 EPS reported -$0.52 revenue$45,571,000

Revenue $22.8M, up 79% YoY; adjusted revenue $22.9M, up 120% YoY excluding prior-period adjustments.
DecisionDx-Melanoma test reports up 70% YoY to 5,128; total dermatology test volume 6,539.
Full-year 2021 revenue guidance raised to $89-93M from prior $80-83M.
Acquired Myriad myPath Laboratory for $33M in May, adding myPath Melanoma test.
Cash at $368M; operating cash flow -$6.4M due to acquisition and Medicare advance recoupment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.